Page 51 - Read Online

receiving vemurafenib in the real-world setting. Cancer Med spectroscopy, cognition, and mood in patients receiving corticosteroid
2015;4:1205-13. therapy. Biol Psychiatry 2004;55:538-45.
100. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman 105. Brown ES. Effects of glucocorticoids on mood, memory, and the
PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi hippocampus. treatment and preventive therapy. Ann N Y Acad Sci
H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert 2009;1179:41-55.
M, Goodman V, Streit M, Kirkwood JM, Schadendorf D. Dabrafenib 106. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager
in patients with Val600Glu or Val600Lys BRAF-mutant melanoma PL, de Jong JR, van Dongen GA, Schroder CP, Lub-de Hooge MN,
metastatic to the brain (BREAK-MB): a multicentre, open-label, de Vries EG. Biodistribution of 89Zr-trastuzumab and PET imaging
phase 2 trial. Lancet Oncol 2012;13:1087-95. of HER2-positive lesions in patients with metastatic breast cancer.
101. Ramanujam S, Schadendorf D, Long GV. Systemic therapies for Clin Pharmacol Ther 2010;87:586-92.
melanoma brain metastases: which drug for whom and when? Chin 107. Gaykema SB, Brouwers AH, Lub-de Hooge MN, Pleijhuis RG,
Clin Oncol 2015;4:25. Timmer-Bosscha H, Pot L, van Dam GM, van der Meulen SB, de
102. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, Jong JR, Bart J, de Vries J, Jansen L, de Vries EG, Schroder CP.
Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio 89Zr-bevacizumab PET imaging in primary breast cancer. J Nucl
M, Hauschild A, Miller WH, Jr., Gascon P, Lotem M, Harmankaya
K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok Med 2013;54:1014-8.
JD. Ipilimumab plus dacarbazine for previously untreated metastatic 108. Lipsman N, Mainprize TG, Schwartz ML, Hynynen K, Lozano AM.
melanoma. N Engl J Med 2011;364:2517-26. Intracranial applications of magnetic resonance-guided focused
103. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen ultrasound. Neurotherapeutics 2014;11:593-605.
JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, 109. Kobus T, McDannold N. Update on Clinical Magnetic Resonance-
van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Guided Focused Ultrasound Applications. Magn Reson Imaging Clin
Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, N Am 2015;23:657-67.
Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba 110. Werner B, Martin E. Transcranial focused ultrasound : Neurological
WJ. Improved survival with ipilimumab in patients with metastatic applications of magnetic resonance-guided high-intensity focused
melanoma. N Engl J Med 2010;363:711-23. ultrasound. Radiologe 2015;55:976-80,982-3.
104. Brown ES, D JW, Frol A, Bobadilla L, Khan DA, Hanczyc M, Rush 111. Ba JL, Jandial R, Nesbit A, Badie B, Chen M. Current and emerging
AJ, Fleckenstein J, Babcock E, Cullum CM. Hippocampal volume, treatments for brain metastases. Oncology 2015;29:250-7.

Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ May 20, 2016 ¦ 175